Advertisement

Chinese Journal of Clinical Oncology

, Volume 2, Issue 3, pp 637–640 | Cite as

Establishment of diagnostic criteria using EBNA1 IgA antibody levels in a high-risk area for nasopharyngeal carcinoma

  • Weimin Cheng
  • Mingfang Ji
  • Yongsheng Zong
  • Yaoliang Gu
  • S Park Ng
  • Xiaoling Li
  • Jilan Yang
  • Yuanqing Guo
Original Articles
  • 6 Downloads

Abstract

Objective

The EBNA1 IgA antibody level of normal and NPC subjects in a high incidence area were analyzed for new diagnostic criteria to improve diagnosis.

Methods

A total of 780 normal and 104 NPC sera were tested for EBNA1 IgA antibody levels by ELISA. Two diagnostic criteria were obtained from sensitivity and specificity data: 1) lower equivocal limit (rOD=1.10) where sensitivity = 95%; and 2) upper equivocal limit (rOD=1.85) where specificity = 95%.

Results

The range and distribution of EBNA1 IgA antibody levels are broad with those of normal subjects (0.093-4.726, mean = 0.850 ± 0.637) overlapping those from NPC subjects (0.235-3.721, mean = 2.241 ±0.875). However, NPC subjects did exhibit significantly higher antibody levels (t= 18.5, P<0.001). Based on the diagnostic criteria, 3 diagnostic categories were established: 1 Positive; 2 Suspected Positive; and 3) Negative. The percentage of NPC subjects falling into these 3 diagnostic categories were 75.13%, 17.44% and 7.44%, respectively and of normal subjects, 4.81%, 17.31%, 77.88% respectively.

Conclusion

Due to the broad distribution and overlapping of antibody levels between normal and NPC subjects in a high incidence area, it is important to have diagnostic criteria that will categorize those with equivocal results to minimize misdiagnosis. The 3 diagnostic categories established in this study will enhance detection and help physicians in their clinical diagnosis.

Keywords

EB virus serological diagnosis nasopharyngeal carcinoma ELISA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shem ST, Wei W, Ng MH. Research on nasopharyngeal carcinoma in recent ten years by University of HongKong Medical College. Chin J Clin Oncol. 1997; 24:645–650.Google Scholar
  2. 2.
    Foong YT, Cheng HM, Sam CK, et al. Serum and Salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear Aantigen (EBNA) are elevated in nasopharyngeal Carcinoma. Int J Cancer. 1990; 45:1061–1064.PubMedCrossRefGoogle Scholar
  3. 3.
    Cao SM, Huang TB, Jian SW, et al. The Relationship between EB Virus ZEBRA IgG Change Regulation and Nasopharyngeal Carcinoma. Cancer Res Prev Treat. 1999; 20:115–117.Google Scholar
  4. 4.
    Liu MT, Lin LS, Yu Y, et al. Use of recombinant Epstein-Barr virus early antigen for detection of antibody in patients with nasopharynhgeal carcinoma. Chung Hua I Hsueh Tsa Chin (Taipei). 1996; 57:7–15.Google Scholar
  5. 5.
    Huang JY, Hu MH. Significance of ELISA detection of EBVIgG/EA antibody in serological diagnosis of nasopharyngeal carcinoma. Chin J Immunol. 2002; 18:142.Google Scholar
  6. 6.
    Zheng YX, Li JZ, Jian SW, et al. Detectiom of salivary Epstein-Barr virus antibodies for early diagnosis of nasopharyngeal carcinoma. Chin J Cancer. 2001; 20:235–238.Google Scholar
  7. 7.
    Cheng WM, Chen GX, Chen HL, et al. Assessment of nasopharyngeal carcinoma risk by EB virus antibody profile. Chin J Oncol. 2002; 24:561–563.Google Scholar
  8. 8.
    Gu YL, Zhang CQ, Ng Park, et al. Study on sero-diagnosis of nasopharyngeal carcinoma using a dual antibody test against recombinant Epstein-Barr virus antigens. Chin J Cancer. 2003; 22:903–906.Google Scholar
  9. 9.
    Cheng MT, Cheng WM, Ji MF, et al. Detection of serum Epstein-Barr virus antibody level by ELISA in normal populations and nasopharyngeal carcinoma patients in Zhongshan City of China. J First Mil Med Univ. 2002; 22: 817–818.Google Scholar
  10. 10.
    Cheng WM, Chen GX, Chen HL, et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Intl J Cancer. 2002; 97:489–492.CrossRefGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association and Springer 2003

Authors and Affiliations

  • Weimin Cheng
    • 1
  • Mingfang Ji
    • 1
  • Yongsheng Zong
    • 2
  • Yaoliang Gu
    • 3
  • S Park Ng
    • 4
  • Xiaoling Li
    • 1
  • Jilan Yang
    • 1
  • Yuanqing Guo
    • 1
  1. 1.Cancer Research of Zhongshan CityGuangdongChina
  2. 2.School of Fundamental MedicineSun Yat-sen UnversityGuangdongChina
  3. 3.Zhongshan Bio-tech Co. Ltd.GuangdongChina
  4. 4.Hong Kong UniversityHong Kong SARChina

Personalised recommendations